- The transaction further enhances market access to the third largest pharmaceutical market
- Fuji Pharma brings a wealth of industry experience in Japan and an excellent women’s healthcare portfolio
- Lotus contributes rich experience of developing complex oral oncology products and access to APAC markets
- Both parties are committed to further portfolio expansion to better serve more customers across Asia
Lotus Pharmaceutical Co., Ltd (“Lotus”, TPEX ticker: 1795) and Fuji Pharma Co. Ltd. (“Fuji”, TSE First Section ticker: 4554), today announced execution of capital and business collaboration agreements. Under the terms of the cash-natural capital collaboration Fuji has acquired a 2.0% stake in Lotus for approximately US$20 million (or NT$ 617 million, JPY 2.2 billion). Lotus has also acquired 3.9% stake in Fuji for an equal sum.
The transaction is designed to further strengthen Lotus and Fuji’s commercial platform in Japan and other key Asian pharmaceutical markets, to explore cross-selling opportunities, realizing synergies in manufacturing and to jointly invest in the development of specialty products for the region.
Commenting on the transaction, Robert Wessman, Chairman of Lotus, said: “I am delighted to welcome such a prestigious investor on board, who brings significant industry experience and rich R&D resources from one of the largest pharmaceutical market. Fuji Pharma is an excellent partner and we are looking forward to collaborating with their high-caliber team as we work to fuel regional growth for Lotus and continue to bring high quality medicines to patients.”
Hirofumi Imai, Chairman of Fuji Pharma, said: “Fuji Pharma is extremely pleased to agree on this partnership with Lotus. At Fuji, we strongly believe in the global competitiveness of the oral oncology and specialty products that Lotus develop and manufacture. Our cross-investment reflects a long-term business collaboration that we are committed to. I look forward to working with Mr. Wessman and the rest of the team at Lotus.”